Biocon MD & CEO On Geopolitical Risks, Shipping Costs & Margin Outlook | Business News | ET Now
ET Now · 05 Nov 2026 · 6 min
Management interview of Biocon Ltd (BIOCON), with 2 key numbers discussed.
- Shreehas Tambe, MD & CEO, Biocon
Biocon confirmed that delayed shipments affecting about 5% of Q2 biopharma sales spilled into Q3 and were recognized in October. Management expects the second half of FY27 to be stronger than the first half, with biosimilar margins returning to the mid-20s as operating leverage improves. Freight and organic solvent cost headwinds have pressured gross margins in generics, with predictability remaining low. For denosumab, the company plans not to chase market share aggressively due to crowded competitive conditions.